The anti-CD20/ anti-cd 3 antibodies combination of anti-PD-1 antibody and bispecific for the treatment of cancer

• 收藏
• 分享

专利权人:

REGENERON PHARMACEUTICALS; INC.

发明人:

BINDU VARGHESE,CARRIE BROWNSTEIN,GAVIN THURSTON,ISRAEL LOWY

申请号：

BR112018012801

公开号：

BR112018012801A2

申请日:

2016.12.21

申请国别(地区):

BR

年份:

2018

代理人:

摘要：

Method the present invention is provided to treat cancer (for example, B cell cancer, such as Hodgkin lymphoma or acute lymphoblastic leukemia), reduce its seriousness or inhibit growth.The method of the present invention includes the antibody or its antigen-binding fragment combined with programmed death 1 (PD 1) receptor-specific that therapeutically effective amount is applied to required individual, are combined with the bispecific antibody for being specifically bound to CD20 and CD3 of therapeutically effective amount.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/